OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear

811 Projects | 561 Researchers | $385,341,463 Invested

2025

Superfluid Dx

Bojk Berghuis

Integrating cfRNA and Proteomics with AI for Next-Generation Alzheimer’s Diagnostics

  • Funding Amount: $911,250
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Active

2025

Alzheimers Disease Data Initiative (ADDI)

Farhad Imam

The Global Neurodegeneration Proteomics Consortium: V2 expansion for ADNI and other key AD datasets

  • Funding Amount: $1,881,800
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Target: Other
  • Status: Active

2025

Stanford University

Michelle James, PhD

Development of new PET radiotracers for detecting and tracking innate immune activation in the whole body and CNS of Alzheimer's disease

  • Funding Amount: $350,385
  • Organization Type: Academic/Nonprofit
  • Program: Biomarkers
  • Status: Active

2025

Emtherapro

Nicholas Seyfried

A novel, accurate plasma proteomic assay for screening and diagnosis of individuals with Alzheimer’s Disease and Alzheimer’s Disease Related Dementia (AD/ADRD)

  • Funding Amount: $499,415
  • Organization Type:
  • Program: Diagnostics Accelerator
  • Status: Active

2025

Vesper Bio ApS

Mads Fuglsang Kjølby

Open-label multiple dosing study in asymptomatic GRN-Frontotemporal dementia patients to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of VES001.

  • Funding Amount: $2,549,203
  • Organization Type:
  • Program: Clinical
  • Status: Active

2025

The University of Texas Southwestern Medical Center at Dallas

Marc Diamond, MD

AAV-mediated clearance of tau aggregates in vivo

  • Funding Amount: $600,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Active

2025

University of Illinois at Chicago

Steven Ackerman, PhD

Development of novel CCR3 chemokine receptor peptide and small molecule functionally selective biased antagonists to treat neuroinflammation in Alzheimer’s disease.

  • Funding Amount: $599,515
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Active

2025

Monash University

Joanne Ryan, PhD

Leveraging a large scale randomized clinical trial to determine whether statins can prevent Alzheimer’s Disease neuropathology and dementia

  • Funding Amount: $424,461
  • Organization Type:
  • Program: Prevention
  • Status: Active

2025

Beth Israel Deaconess Medical Center

Chenxi Qiu, PhD

A new therapeutic antibody for Frontotemporal Dementia

  • Funding Amount: $349,590
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Active

2025

University of Pennsylvania

James Shorter, PhD

Defining oligonucleotide therapeutics that reverse FUS proteinopathy

  • Funding Amount: $350,000
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Status: Active
View More